Moberg Pharma AB (publ) (MOB) Fair Value & Analysis
Healthcare · SE · Market cap 443M SEK (≈ $46.3M) · ISIN SE0020353928
Risks
Fair value as of: Aug 23, 2026
From 1 valuation models · updated 8 days ago
Share price +11.8% over the past month.
Below-average quality, and trading another 174% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (kr 4.97). The favourable scenario is already priced in.
- Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (kr 2.63 to kr 4.97) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 23, 2026.
How to read this chart
60‑month range kr 4.13 – kr 47.06 · fair‑value band kr 2.63 – kr 4.97 · the kr 10.92 price screens above the kr 3.98 fair value. Dashed = 300-day average. As of Aug 23, 2026.
Analysis
Moberg Pharma AB (publ) (MOB) currently trades at kr 10.92, while our model-based Fair Value estimate is kr 3.98, implying the stock looks roughly 63.6% overvalued today. The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Revenue grew 101.4% year over year. It earns a return on equity of -4.0%. The balance sheet holds a net cash position of 228M SEK. Fundamentals as of Aug 23, 2026
Our scenario range runs from kr 2.63 (bear case) to kr 4.97 (bull case); at kr 10.92, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 23% below its 52-week high and 45% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -45% fair-value upside, at -64%, MOB screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when MOB reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 33 · Market factors (momentum, volatility) 53
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013.
Full company description
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Moberg Pharma AB (publ) reported revenue of kr 13.5M in FY2025 versus kr 210M in FY2021, a compound −49.6%/yr. Reported net income was −kr 27.2M in FY2025.
MOB screens 174% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 637 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | -24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | -38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | -69% |
| Haleon plc HLN | $10.11 | $7.64 | -24% |
| Teva Pharmaceutical Industries Limited TEVA | $37.92 | $15.33 | -60% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | -45% |
| Zoetis Inc ZTS | $77.52 | $104.88 | +35% |
| Hansoh Pharmaceutical Group 3692 | HK$33.50 | HK$16.14 | -52% |
Compare Moberg Pharma AB (publ) with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Moberg Pharma AB (publ) (MOB) overvalued or undervalued?
What is the fair value of MOB?
What is the quality score of MOB?
What is the net profit margin of MOB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Moberg Pharma AB (publ) in the live analysis
One click puts Moberg Pharma AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.